Press release
Interstitial Cystitis Clinical Trials 2024 (Updated): FDA Approvals, Medication, Pipeline, Therapies, Mechanism of Action, ROA and Companies by DelveInsight
Interstitial Cystitis Clinical Trials
(Albany, USA) DelveInsight's, "Interstitial Cystitis Pipeline Insight, 2024" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
For Interstitial Cystitis Emerging drugs, the Interstitial Cystitis pipeline analysis report provides a 360 degrees view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Pyelonephritis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Request for Sample Pages: Interstitial Cystitis Pipeline Analysis [https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key highlights from the Interstitial Cystitis Pipeline report:
* The Interstitial Cystitis Pipeline report offers a rich analysis of 8+ key players and 10+ key therapies.
* Interstitial Cystitis pipeline comprises therapies in different stages of the clinical phase such as include Certolizumab pegol, SI-722, IW-3300, and many others expected to enter the Interstitial Cystitis market in the coming years.
* Key companies strengthening the Interstitial Cystitis Pipeline are Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and many others.
* In July 2024, Ironwood Pharmaceuticals, Inc announced results of a Phase 2 Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate the Efficacy, Safety, and Tolerability of 2 Dose Levels of IW-3300 Administered Rectally for 12 Weeks to Treat Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
* In June 2024, Imbrium Therapeutics announced results of a Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome
* In May 2024, Vaneltix Pharma, Inc announced results of a Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity
Some of the key Interstitial Cystitis companies working in the market are:
* Merck & Co
* Teva Pharmaceutical Industries
* Integrative Therapeutics, Inc.
* Lipella Pharmaceuticals, Inc.
* Addex Therapeutics
* Seikagaku Corporation
* UCB
* Alivio Therapeutics
* Imbrium Therapeutics
* Ironwood Pharmaceuticals, And Many Others.
Learn more about the emerging Interstitial Cystitis pipeline therapies @ Interstitial Cystitis Treatment Market [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Interstitial cystitis Overview:
Interstitial cystitis (IC), also called bladder pain syndrome, is a chronic, or long-lasting, condition that causes painful urinary symptoms. Symptoms of IC may be different from person to person. For example, some people feel mild discomfort, pressure, or tenderness in the pelvic area. Other people may have intense pain in the bladder or struggle with urinary urgency, the sudden need to urinate, or frequency, the need to urinate more often. IC can occur at any age, including during childhood, but is most common in adult women and men. About twice as many women are affected as men.1 However, more men may struggle with IC than researchers originally thought. Some research suggests that women are more likely to develop IC if they have a history of being physically traumatized
Interstitial Cystitis Emerging Drugs
Certolizumab pegol: UCB
Certolizumab pegol (Cimzia) developed by UCB, Belgium is a recombinant, humanized F(ab)' fragment of an antibody conjugated to polyethylene glycol to enhance its plasma half-life. It is in phase 3 stage of development for the treatment of Interstitial cystitis.
SI-722: Seikagaku Corporation
SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase I/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.
Request a sample and discover the recent advances in Interstitial Cystitis treatment drugs @ Interstitial Cystitis Therapeutic Assessment [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Interstitial Cystitis Analytical Perspective by DelveInsight
* In-depth Interstitial Cystitis Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
* Interstitial Cystitis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Request a Interstitial Cystitis pipeline report sample @ Interstitial Cystitis Drugs and Therapies [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Interstitial Cystitis pipeline report
* The Interstitial Cystitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Interstitial Cystitis across the complete product development cycle, including all clinical and nonclinical stages.
* It comprises of detailed profiles of Interstitial Cystitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
* Detailed Interstitial Cystitis research and development progress and trial details , results wherever available, are also included in the pipeline study.
* Coverage of dormant and discontinued pipeline project s along with the reasons if available across Interstitial Cystitis.
Dive deep into rich insights for new drugs for Interstitial Cystitis treatment, visit @ Interstitial Cystitis Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content:
Introduction
Executive Summary
Interstitial Cystitis: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Interstitial Cystitis Pipeline Therapeutics
* Comparative Analysis
Interstitial Cystitis Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
* Comparative Analysis
Certolizumab pegol: UCB
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
* Comparative Analysis
Drug name: Company name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
* Comparative Analysis
Drug name: Company name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Interstitial Cystitis Preclinical and Discovery Stage Products
* Comparative Analysis
LYT 503: PureTech Health
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Inactive Interstitial Cystitis Products
* Comparative Analysis
Interstitial Cystitis Companies
Interstitial Cystitis Key Products
Interstitial Cystitis Unmet Needs
Interstitial Cystitis Market Drivers and Barriers
Interstitial Cystitis Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Companies
Appendix
About DelveInsight
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-cystitis-clinical-trials-2024-updated-fda-approvals-medication-pipeline-therapies-mechanism-of-action-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Interstitial Cystitis Clinical Trials 2024 (Updated): FDA Approvals, Medication, Pipeline, Therapies, Mechanism of Action, ROA and Companies by DelveInsight here
News-ID: 3655743 • Views: …
More Releases from ABNewswire
Ancestry India DNA Unveils Revolutionary Health Innovation at SIIMA Awards in Du …
Ancestry India DNA offers innovative DNA mapping and testing focused on accessible, personalized healthcare for Indian citizens. By providing insights into family health history, it helps prevent hereditary diseases and empowers individuals to make informed health decisions. With an emphasis on care and support, the company prioritizes the well-being of the people of India, aiming to revolutionize healthcare through DNA analysis and proactive health management.
In a groundbreaking moment for personalized…
John Mitchell Available for Podcast Interviews: Unveiling "The Missing Secret" f …
John Mitchell, entrepreneur and thought leader, reveals the missing piece of the Think and Grow Rich success formula in his upcoming book, The Missing Secret, offering a practical, science-backed 12-minute-a-day technique to unlock hidden potential and achieve extraordinary results. He is now available for podcast interviews.
John Mitchell, a seasoned entrepreneur and thought leader, is thrilled to announce his availability for podcast interviews to discuss his upcoming book, The Missing Secret…
Branex Redefines Digital Innovation with Next-Level Generative AI and Strategic …
Branex is excited to announce the launch of two groundbreaking services - Generative AI services and Staff Augmentation solutions - designed to help businesses accelerate their digital transformation journey. Branex redefines how businesses take care of many modern-day business challenges. From agile startups to global enterprises, we offer the digital tools you need to seize the moment & beat the competition.
Branex [https://branex.com/] is excited to announce the launch of two…
Top Kitchen Remodeling Contractors in Boca Raton, FL, Transform Homes with Innov …
Boca Raton, FL - ABC Construction Building, recognized as one of the premier kitchen remodeling contractors in Boca Raton, FL [https://www.abnewswire.com/pressreleases/home-builders-in-delray-beach-fl-set-new-standard-with-exceptional-project-planning_710446.html], is renowned for transforming kitchens into modern, highly functional, and aesthetically pleasing spaces. With over three decades of experience in the industry, the firm specializes in customizing kitchen designs that cater not only to homeowners' unique tastes but also enhance the overall functionality of their living spaces.
Israel Morag, the…
More Releases for Interstitial
Global Interstitial Pneumonia Market Growth 2020-2025
Global Interstitial Pneumonia Market Overview:
The global Interstitial Pneumonia market is expected to grow at a significant pace, reports GLOBAL INFO RESEARCH. Its latest research report, titled [Global and United States Interstitial Pneumonia Market 2020 by Company, Type and Application, Forecast to 2025], offers a unique point of view about the global market. Analysts believe that the changing consumption patterns are expected to have a great influence on the overall market. For a…
Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018
Interstitial lung disease is a type of inflammatory disease that affects and thickens the interstitium of the lungs.
Download the sample report @ https://www.pharmaproff.com/request-sample/1126
The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues.
Get the detailed analysis @ https://www.pharmaproff.com/report/interstitial-lung-disease-therapeutics-pipeline-analysis
Some of the types of the condition include…
Interstitial Cystitis-Pipeline Review H2 2018
Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome)-Pipeline Review, H2 2018
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome)-Pipeline Review, H2 2018, provides an overview of the Interstitial Cystitis (Painful Bladder SyndromeBladder Pain Syndrome) (Central Nervous System) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort…
Interstitial Cystitis Therapeutics Pipeline Analysis, Patent, Designation & Coll …
Interstitial cystitis, also known as painful bladder syndrome is a condition that causes painful urinary symptoms that differs from person to person. Mild discomfort, tenderness in the pelvic area, bladder pain and increased frequency to urinate, are some of the observed symptoms in the patients suffering from interstitial cystitis. Irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia and autoimmune diseases are also observed to be associated with interstitial cystitis in the…
Interstitial Cystitis-Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome)-Pipeline Review, H2 2017, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity,…
Interstitial Cystitis Market Research Report | Analysis & Trends 2025
Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, with occasional pain in either the lower abdomen, pelvic, or lower back. The patient could experience pain raging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume,…
